FDA declines to approve Camurus' rare hormone disorder drug

 The U.S. Food and Drug Administration has declined to approve Camurus' (CAMX.ST) drug for the treatment of a rare hormonal disorder due to deficiencies at a third-party manufacturing facility, the Swedish drugmaker said late Monday.